Press release dated January 12th, 2022 in Globe Newswire. "Mr. Wolf further noted we are also making significant process with HS-110 and expect to file for an end of phase 2 meeting with the FDA this quarter. Our goal for this meeting is to discuss potential Phase 3 registration pathways for HS-110. Although this submission is taking longer than expected, we believe we have prepared a very comprehensive package and look forward to the FDA's feedback." Very good outlook for 2022. By the end of the year hoping for double-digit price, maybe even $20!